Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of paclitaxel in combination with cyclophosphamide and dexamethasone in chinese patients with relapsed/refractory multiple myeloma.


Clinical Trial Description

Treatment for relapsed/refractory multiple myeloma (MM)remains a crucial challenge.The investigators have previously shown that the combination of paclitaxel and cyclophosphamide acts synergistically to induce apoptosis of myeloma cells in vitro. Based on these preclinical studies, the investigators initiated a phase II clinical trial of paclitaxel 175 mg/m(2) IV over 3 h d1 combined with cyclophosphamide 200 mg/m(2) IV over 30-60 min d1,3,5 and dexamethasone 20mg IV over 30-60 min d1-4 in patients with relapsed or refractory MM. This regimen was administered every four weeks for a total of six cycles ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02985333
Study type Interventional
Source Sun Yat-sen University
Contact
Status Withdrawn
Phase Phase 2
Start date January 2014
Completion date June 2019

See also
  Status Clinical Trial Phase
Completed NCT03944057 - A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma Phase 2
Recruiting NCT06084962 - A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma Phase 1
Active, not recruiting NCT04613557 - Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT03353545 - Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life Conditions
Withdrawn NCT02986451 - Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma Phase 2
Completed NCT02290431 - Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma Phase 2